专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009095925A3 POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS 审中-公开
标题翻译：多肽和多核苷酸，以及作为药物和生物学药物目标的用途
公开(公告)号：WO2009095925A3
公开(公告)日：2010-04-15
申请号：PCT/IL2009000123
申请日：2009-02-01
申请人： COMPUGEN LTD , LEVIN ZURIT , ROSENBERG AVI YESHAH , ROTMAN GALIT , TOPORIK AMIR , DASSA LIAT , BEIMAN MERAV , LEVY OFER , NEMZAR SERGEY , WALACH SHIRA , SAMEACH-GREENWALD SHIRLEY , MONTIA EVE , KINAR YARON , COHEN-DAYAG ANAT
发明人： LEVIN ZURIT , ROSENBERG AVI YESHAH , ROTMAN GALIT , TOPORIK AMIR , DASSA LIAT , BEIMAN MERAV , LEVY OFER , NEMZAR SERGEY , WALACH SHIRA , SAMEACH-GREENWALD SHIRLEY , MONTIA EVE , KINAR YARON , COHEN-DAYAG ANAT
IPC分类号： C07K14/47
CPC分类号： A61K39/3955 , C07K14/47 , C07K16/28 , C07K16/2887 , C07K16/2896 , C07K2317/21 , C07K2317/34
摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagnostic and therapeutic usages. This invention further relates to the discovery of extracellular domains of KIAA0746 and its variants, CD20 and its variants, CD55 and its variants, which are suitable targets for immunotherapy, cancer therapy, treatment of inflammatory, allergic and autoimmune disorders, and drug development.
摘要翻译：本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。更具体地，本发明提供了针对KIAA0746，CD20或CD55抗原的治疗性抗体，其在癌症和特异性血细胞中差异表达，以及诊断和治疗用途。本发明还涉及KIAA0746及其变体CD20及其变体CD55及其变体的细胞外结构域的发现，其是免疫治疗，癌症治疗，炎症，过敏和自身免疫性疾病的治疗以及药物开发的合适靶标。

2. 发明申请

WO2010067308A2 POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS 审中-公开
标题翻译：多肽和多核苷酸，以及作为药物和生物学药物目标的用途
公开(公告)号：WO2010067308A2
公开(公告)日：2010-06-17
申请号：PCT/IB2009055585
申请日：2009-12-08
申请人： COMPUGEN LTD , LEVINE ZURIT , ROSENBERG AVI YESHAH , ROTMAN GALIT , TOPORIK AMIR , KINAR YARON , NEMZAR SERGEY , COHEN-DAYAG ANAT , WALACH SHIRA , SAMEACH-GREENWALD SHIRLEY , DASSA LIAT , BEIMAN MERAV , MONTIA EVE , NOVIK AMIT , LEVY OFER
发明人： LEVINE ZURIT , ROSENBERG AVI YESHAH , ROTMAN GALIT , TOPORIK AMIR , KINAR YARON , NEMZAR SERGEY , COHEN-DAYAG ANAT , WALACH SHIRA , SAMEACH-GREENWALD SHIRLEY , DASSA LIAT , BEIMAN MERAV , MONTIA EVE , LEVY OFER
IPC分类号： C07K16/28 , C07K14/705
CPC分类号： C07K16/28 , A61K38/00 , A61K39/39558 , A61K2039/505 , C07K14/47 , C07K16/30 , C07K16/3015 , C07K16/3038 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C12Q1/6886 , C12Q2600/136 , G01N33/57484 , G01N33/577 , G01N2333/47
摘要： This invention relates to a novel target for production of immune and non¬ immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KRTCAP3, FAM26F, MGC52498, FAM70A or TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages. This invention further relates to extracellular domains of KRTC AP3, FAM26F, MGC52498, FAM70A and TMEM154 proteins and variants, and therapeutic usages thereof.
摘要翻译：本发明涉及用于产生基于免疫和非免疫的治疗剂和疾病诊断的新靶标。更具体地，本发明提供针对在癌症中差异表达的KRTCAP3，FAM26F，MGC52498，FAM70A或TMEM154抗原以及诊断和治疗用途的治疗性抗体。本发明还涉及KRTC AP3，FAM26F，MGC52498，FAM70A和TMEM154蛋白质和变体的细胞外结构域及其治疗用途。

3. 发明申请

WO2009032845A3 POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS 审中-公开
标题翻译：多肽和多核苷酸及其用作生产药物和生物制品的药物目标
公开(公告)号：WO2009032845A3
公开(公告)日：2009-05-28
申请号：PCT/US2008075122
申请日：2008-09-03
申请人： COPUGEN LTD , COMPUGEN USA INC , LEVINE ZURIT , ROSENBERG AVI , ROTMAN GALIT , NOVIK AMIT , TOPORIK AMIR , KINAR YARON , NEMZER SERGEY , KOIFMAN CYNTHIA , BEIMAN MERAV , DASSA LIAT , WALACH SHIRA , MONTIA EVE , SAMEACH-GREENWALD SHIRLEY , PERGAM TANIA , MILO DALIT , COHEN-DAYAG ANAT , LEVY OFER , BUBIS MARINA
发明人： LEVINE ZURIT , ROSENBERG AVI , ROTMAN GALIT , NOVIK AMIT , TOPORIK AMIR , KINAR YARON , NEMZER SERGEY , KOIFMAN CYNTHIA , BEIMAN MERAV , DASSA LIAT , WALACH SHIRA , MONTIA EVE , SAMEACH-GREENWALD SHIRLEY , PERGAM TANIA , MILO DALIT , COHEN-DAYAG ANAT , LEVY OFER , BUBIS MARINA
IPC分类号： A61K39/00
CPC分类号： C07K16/30 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/0005 , A61K39/0008 , A61K39/39 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/545 , A61N5/10 , C07K14/00 , C07K14/47 , C07K14/4702 , C07K14/705 , C07K14/70503 , C07K14/82 , C07K16/28 , C07K2317/21 , C07K2317/76 , C07K2319/00 , C07K2319/30 , C07K2319/60 , C07K2319/70 , G01N33/564 , G01N33/57419 , G01N33/57423 , G01N33/57449 , G01N33/57484 , G01N33/57492 , G01N2500/04
摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.
摘要翻译：本发明涉及用于生产基于免疫和非免疫的治疗剂和用于疾病诊断的新型靶。更具体地说，本发明提供了针对VSIG1，ILDR1，LOC253012，AI216611，C1ORF32或FXYD3抗原的治疗性抗体，其是预测的共刺激家族成员并且在癌症包括肺癌，卵巢癌和结肠癌中差异表达，以及诊断和治疗用法。还提供了这些抗体用于调节B7共刺激和相关疗法如治疗自身免疫的用途。本发明进一步涉及VSIG1及其变体，FXYD3及其变体，ILDR1及其变体，LOC253012及其变体，AI216611及其变体，以及C1ORF32及其变体的细胞外结构域的发现，它们是免疫治疗，癌症治疗和药物开发。

7. 发明申请

WO2012090150A3 NEW CELL-PENETRATING PEPTIDES AND USES THEREOF 审中-公开
标题翻译：新的细胞渗透肽及其用途
公开(公告)号：WO2012090150A3
公开(公告)日：2012-11-01
申请号：PCT/IB2011055956
申请日：2011-12-26
申请人： COMPUGEN LTD , JACOB ETAIL , TOPORIK AMIR , SHEMESH RONEN , LEVY OFER
发明人： JACOB ETAIL , TOPORIK AMIR , SHEMESH RONEN , LEVY OFER
IPC分类号： A61K47/48 , C07K14/47 , C07K14/78
CPC分类号： A61K47/48246 , A61K47/62 , C07K14/47 , C07K14/78 , C07K2319/01
摘要： The present invention is related to peptides, which are suitable for use as cell-penetrating peptides (CPPs), variants thereof and/or complexes, fusion molecules and/or conjugates comprising same, use thereof for manufacture of compositions for diagnosing, treating and/or preventing of medical conditions.
摘要翻译：本发明涉及适合用作细胞穿透肽（CPP），其变体和/或复合物，融合分子和/或包含其的缀合物的肽，其用于制造用于诊断，治疗和/ 或预防医疗条件。

8. 发明申请

WO2010010551A3 ANGIOPOIETIN DERIVED PEPTIDES 审中-公开
标题翻译：神经肽衍生肽
公开(公告)号：WO2010010551A3
公开(公告)日：2010-05-14
申请号：PCT/IL2009000709
申请日：2009-07-20
申请人： COMPUGEN LTD , KLIGER YOSSEF , BORUKHOV ITAMAR , LEVY OFER , TIRAN ZOHAR , WOOL ASSAF , SCHREIBER EHUD , AMIR ANAT , LEVINE ZURIT , TOPORIK AMIR
发明人： KLIGER YOSSEF , BORUKHOV ITAMAR , LEVY OFER , TIRAN ZOHAR , WOOL ASSAF , SCHREIBER EHUD , AMIR ANAT , LEVINE ZURIT , TOPORIK AMIR
IPC分类号： C07K14/515
CPC分类号： C07K14/515 , A61K38/14 , A61K38/1891 , A61K45/06 , C07K9/00 , C07K9/001
摘要： In at least some embodiments, the subject invention provides angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition comprising them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins comprising them.
摘要翻译：在至少一些实施方案中，本发明提供血管生成素衍生的肽或其同系物或衍生物，包含它们的药物组合物，其用于治疗和用于制备药物的用途，治疗广泛的病症，病症和疾病，编码它们的核苷酸序列，针对其表位的抗体和包含它们的融合蛋白。

9. 发明申请

WO2009093246A3 CLUSTERIN DERIVED PEPTIDE 审中-公开
标题翻译： CLUSTERIN衍生肽
公开(公告)号：WO2009093246A3
公开(公告)日：2009-11-26
申请号：PCT/IL2009000093
申请日：2009-01-22
申请人： COMPUGEN LTD , KLIGER YOSSEF , LEVY OFER , BORUKHOV ITAMAR , WOOL ASSAF , SCHREIBER EHUD , AMIR ANAT , LEVINE ZURIT , TIRAN ZOHAR , OREN ANAT , TOPORIK AMIR
发明人： KLIGER YOSSEF , LEVY OFER , BORUKHOV ITAMAR , WOOL ASSAF , SCHREIBER EHUD , AMIR ANAT , LEVINE ZURIT , TIRAN ZOHAR , OREN ANAT , TOPORIK AMIR
IPC分类号： A61K38/17 , C07K14/775 , C07K16/18
CPC分类号： C07K14/775 , A61K38/00
摘要： The subject invention provides clusterin-derived peptides or homologs or derivatives thereof, pharmaceutical composition comprising them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins comprising them.
摘要翻译：本发明提供簇蛋白衍生的肽或其同系物或衍生物，包含它们的药物组合物，其用于治疗和制备药物的用途，用于治疗广泛的病症，疾病和疾病的方法，编码它们是针对其表位的抗体和包含它们的融合蛋白。

10. 发明专利

GB2503630A Stabilizing apparatus for inclined legs 未知
公开(公告)号：GB2503630A
公开(公告)日：2014-01-01
申请号：GB201319072
申请日：2012-04-02
申请人： LEVY OFER , WOLF URI
发明人： LEVY OFER , WOLF URI
IPC分类号： A47B96/06
摘要： Stabilizing apparatus for inclined legs comprises a thigh engageable portion extending generally transversally along the width of the lap of a subject with which the apparatus is bodily engaged, two spaced appendage portions extending downwardly from the thigh engageable portion, a foot engageable portion positionable on an underlying surface, and a portion, such a connecting element and tensioning device, extending from each of the two appendage portions to a foot engageable portion. The two appendage portions are positionable to be substantially in contact with the lateral side of a thigh of the subject. A loop is defined such that each of the portions extending from an appendage portion to a foot engageable portion is suitably tensioned so as to apply forces to a foot engageable portion for resisting a forward foot sliding motion and to an appendage portion for resisting relative transversal motion of an inclined leg.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式